Regulatory News:
This agreement opens a new field of applications for Cellectis bioresearch technologies
Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of Cellectis (Paris:ALCLS), and Recombinetics, a specialist in biogenetics, announced today that they have entered a development and license agreement on the creation of transgenic large livestock.
Recombinetics creates, in accordance with biosafety and animal well-being requirements, large livestock for agricultural, biomedical and bioproduction applications. Following this agreement, Recombinetics will use Cellectis bioresearch's engineered nucleases to conceive animals with improved genetic features.
The agreement, which will run for 3 years, is exclusive for swine, cattle and sheep and non-exclusive for goat. It broadens the field of applications for the genome customization tools designed and produced by Cellectis bioresearch, emphasizing the versatility of its nucleases.
"We have been amazed by the enthusiasm of the Recombinetics management team and the company's robust results in the genetic engineering of large livestock", said Marc Le Bozec, CEO of Cellectis bioresearch. "Applying our technologies in this new field of application should enable Recombinetics to accelerate its development on this promising market."
"This license enables us to apply the full potential of precision genetics to a variety of livestock applications. In agriculture we will focus on the acceleration of breeding programs by rapid allele introgression. In the biomedical space we will emphasize the addition of new characteristics to animals used in therapeutic development", said Scott Fahrenkrug, CEO of Recombinetics.
Under the terms of the agreement, Cellectis bioresearch is eligible to sales-based milestones of up to $50M and to royalties on the sales generated by the products developed during this collaboration.
About Cellectis bioresearch
Cellectis bioresearch was
incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June
2008. It provides life science researchers with ready- and easy-to-use
tools for genome customization. These tools, based on sequence specific
nucleases, enable the engineering of cells with optimized features for
drug discovery, protein production and gene functional studies. The
genome customization products and services can be purchased online from www.cellectis-bioresearch.com.
Check
the website for more information.
Follow Cellectis bioresearch on
twitter : http://twitter.com/genegineer
About Cellectis
Cellectis improves life by applying its
genome engineering expertise to a broad range of applications, including
agriculture, bioresearch and human therapeutics. Cellectis is listed on
the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
For
further information about Cellectis, visit our website at: www.cellectis.com
Follow
Cellectis on twitter : http://twitter.com/cellectis
About Recombinetics
Recombinetics is a privately held
company with extensive international relationships in agriculture and
animal biotechnology. For further information about recombinetics, visit
at www.recombinetics.com.
Follow Recombinetics on twitter: http://twitter.com/recombinetics
Disclaimer
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer to buy or subscribe, for shares in Cellectis in
any country. This press release contains forward-looking statements that
relate to the Company's objectives based on the current expectations and
assumptions of the Company's management only and involve unforeseeable
risk and uncertainties that could cause the Company to fail to achieve
the objectives expressed by the forward-looking statements above.
Contacts:
Cellectis
Sylvie Delassus
Senior VP Corporate
Communication
Tel: + 33 (0)1 41 83 99 00
Cell: +33 (0)6 26 54
33 18
media@cellectis.com
or
Recombinetics
Mark
Walton
Chief Marketing Officer
Tel: 512-799-1636
mark@recombinetics.com
